FTRE · Fortrea Holdings Inc.
$17.41
-0.41 (-2.30%)
At close · Aug 14
Market Cap
$1.66B
Shares
95.10M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.41
Open$17.65
Day$16.84–17.84
52W close$7.73–20.70
Avg vol 30d1.5M
Short int11.2M · 11.7% float · 6.6d
Short vol74%
Last earningsJul 29, 2026
DataJun 2023–Aug 2026
Filing10-Q · Jul 29
Up next
Next earnings call
Oct 25, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 29, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bearish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+24%
above
Price vs 50-day avg
−2%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
75%
mid-range
Momentum
relative strength
1-month return
−2%
trailing
6-month return
+61%
trailing
YTD return
+1%
this year
Relative strength
+47%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $18 › 200d $14 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +44 funds added
Insider flow
Distributing
Net -$4.4M over 90 days · 100% sells
Short interest
Rising
11.74% of float · ▲ +8.8% MoM · 6.6 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
329 holders — mid 3-yr range
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
+1%
Y/Y
EPS growth
−195%
Y/Y
Balance sheet
$878.2M
net debt
Quant / Vol
risk profile
Volatility
75%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 29, 2026
Revenue
· full-year 2026
$2.62B – $2.69B
Adjusted EBITDA
· full-year 2026
$205M – $220M
Prior guidance
period ended
· from the 8-K filed Nov 5, 2025
Revenue
· full year 2025
$2.7B – $2.75B
Adjusted EBITDA
· full year 2025
$175M – $195M
Guided vs delivered
· last 2 settled
Revenue
full year 2025
guided $2.7B – $2.75B
$2.72B
In line
Total revenue
full-year 2024
guided $3.14B – $3.21B
$2.7B
Miss −15.1%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+24%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
75%
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $18 › 200d $14 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +44 funds added
Insider flow
Distributing
Net -$4.4M over 90 days · 100% sells
Short interest
Rising
11.74% of float · ▲ +8.8% MoM · 6.6 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
329 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $8
Now $17 · 75%
Range high $21
vs 200-day avg +24%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $58.7M | the second quarter ended June 30, 2026 | — |
| Backlog | $7.8B | as of June 30, 2026 | — |
| Book-to-bill ratio | 1.06 | the second quarter ended June 30, 2026 | — |
|
|
|||
| Free cash flow non-GAAP | $19.9M | the second quarter ended June 30, 2026 | — |
| Operating cash flow | $113.5M | full year ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FTRE
this stock
Fortrea Holdings Inc.
|
$1.66B | +0.9% | +1.0% | — | 11.7% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.25B | +11.6% | +46.2% | 30.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.69B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FTRE | -5.5% | -2.0% | +60.6% | -9.2% | +0.9% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -5.9% | -6.4% | +46.8% | -13.1% | -12.9% |
Key facts
CIK
1965040
CUSIP
34965K107
13F (30d)
313 filings
300 filers
Visit website
Investor relations